Dasatinib is an orally available TKI of ABL1, SRC family kinases, KIT, and PDGFRα/β, and has been approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) (Table 4) [502,503]. The gene discussed is KIT; the disease is acute lymphoblastic leukemia.